{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:07:25Z","timestamp":1791022045471,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3-4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.2119\/molmed.2008.00118","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T21:28:37Z","timestamp":1236202117000},"page":"95-100","source":"Crossref","is-referenced-by-count":18,"title":["High Serum A\u03b2 and Vascular Risk Factors in First-Degree Relatives of Alzheimer\u2019s Disease Patients"],"prefix":"10.1186","volume":"15","author":[{"given":"Laila","family":"Abdullah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Luis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghania","family":"Ait-ghezala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Mouzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Parrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles A.","family":"Mullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcie","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,3,1]]},"reference":[{"key":"15030095_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/00019052-200008000-00003","volume":"13","author":"A Tandon","year":"2000","unstructured":"Tandon A, Rogaeva E, Mullan M, St George-Hyslop PH. (2000) Molecular genetics of Alzheimer\u2019s disease: the role of beta-amyloid and the presenilins. Curr. Opin. Neurol. 13:377\u201384.","journal-title":"Curr. Opin. Neurol."},{"key":"15030095_CR2","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","volume":"61","author":"R Mayeux","year":"2003","unstructured":"Mayeux R, et al. (2003) Plasma A\u03b240 and A\u03b242 and Alzheimer\u2019s disease: relation to age, mortality, and risk. Neurology. 61:1185\u20139.","journal-title":"Neurology"},{"key":"15030095_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1196\/annals.1397.082","volume":"1096","author":"T Casoli","year":"2007","unstructured":"Casoli T, et al. (2007) Release of beta-amyloid from high-density platelets: implications for Alzheimer\u2019s disease pathology. Ann. N. Y. Acad. Sci. 1096:170\u20138.","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"15030095_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1474-4422(06)70501-4","volume":"5","author":"M Oijen van","year":"2006","unstructured":"van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM (2006). Plasma A\u03b21-40 and A\u03b21-42 and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 5:655\u201360.","journal-title":"Lancet Neurol."},{"key":"15030095_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2006.09.002","volume":"29","author":"I Blasko","year":"2008","unstructured":"Blasko I, et al. (2008) Conversion from cognitive health to mild cognitive impairment and Alzheimer\u2019s disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol. Aging. 29:1\u201311.","journal-title":"Neurobiol. Aging."},{"key":"15030095_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.neulet.2007.09.058","volume":"428","author":"L Abdullah","year":"2007","unstructured":"Abdullah L, et al. (2007) The influence of diagnosis, intra- and inter-person variability on serum and plasma A\u03b2 levels. Neurosci. Lett. 428:53\u20138.","journal-title":"Neurosci. Lett."},{"key":"15030095_CR7","first-page":"1","volume":"15","author":"CA Luis","year":"2008","unstructured":"Luis CA, et al. (2008) Serum \u03b2-amyloid levels correlate with cognitive impairment. Neuropsychol. Dev. Cogn. B. Aging Neuropsychol. Cogn. 15:1\u201316.","journal-title":"Neuropsychol. Dev. Cogn. B. Aging Neuropsychol. Cogn."},{"key":"15030095_CR8","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1126\/science.290.5500.2303","volume":"290","author":"N Ertekin-Taner","year":"2000","unstructured":"Ertekin-Taner N, et al. (2000) Linkage of plasma A\u03b242 to a quantitative locus on chromosome 10 in late-onset Alzheimer\u2019s disease pedigrees. Science. 290:2303\u20134.","journal-title":"Science"},{"key":"15030095_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1212\/01.wnl.0000278386.00035.21","volume":"70","author":"N Ertekin-Taner","year":"2008","unstructured":"Ertekin-Taner N, et al. (2008) Plasma amyloid \u03b2 protein is elevated in late-onset Alzheimer disease families. Neurology 70:596\u2013606.","journal-title":"Neurology"},{"key":"15030095_CR10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1006\/nbdi.1999.0247","volume":"6","author":"C Jonghe De","year":"1999","unstructured":"De Jonghe C, et al. (1999) Evidence that A\u03b242 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype. Neurobiol. Dis. 6:280\u20137.","journal-title":"Neurobiol. Dis."},{"key":"15030095_CR11","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, et al. (1996). Secreted amyloid \u03b2-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nat. Med. 2:864\u201370.","journal-title":"Nat. Med."},{"key":"15030095_CR12","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/brain\/awh179","volume":"127","author":"K Sleegers","year":"2004","unstructured":"Sleegers K, et al. (2004). Familial clustering and genetic risk for dementia in a genetically isolated Dutch population. Brain. 127(Pt 7):1641\u20139.","journal-title":"Brain"},{"key":"15030095_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/0304-3940(94)90026-4","volume":"174","author":"H Houlden","year":"1994","unstructured":"Houlden H, et al. (1994). Confirmation that familial clustering and age of onset in late onset Alzheimer\u2019s disease are determined at the apolipoprotein E locus. Neurosci. Lett. 174:222\u20134.","journal-title":"Neurosci. Lett."},{"key":"15030095_CR14","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jama.1997.03540340056033","volume":"277","author":"DA Evans","year":"1997","unstructured":"Evans DA, et al. (1997). Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons. JAMA. 277:822\u20134.","journal-title":"JAMA"},{"key":"15030095_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1076-7460.2007.06696.x","volume":"16","author":"C Rosendorff","year":"2007","unstructured":"Rosendorff, C, Beeri MS, Silverman JM. (2007). Cardiovascular risk factors for Alzheimer\u2019s disease. Am. J. Geriatr. Cardiol. 16:143\u20139.","journal-title":"Am. J. Geriatr. Cardiol."},{"key":"15030095_CR16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(96)90608-X","volume":"347","author":"I Skoog","year":"1996","unstructured":"Skoog I, et al. (1996). 15-year longitudinal study of blood pressure and dementia. Lancet. 347:1141\u20135.","journal-title":"Lancet"},{"key":"15030095_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0197-4580(00)00096-8","volume":"21","author":"LJ Launer","year":"2000","unstructured":"Launer LJ, et al. (2000). Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol. Aging 21:49\u201355.","journal-title":"Neurobiol. Aging"},{"key":"15030095_CR18","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1136\/bmj.322.7300.1447","volume":"322","author":"M Kivipelto","year":"2001","unstructured":"Kivipelto M, et al. (2001). Midlife vascular risk factors and Alzheimer\u2019s disease in later life: longitudinal, population based study. BMJ 322:1447\u201351.","journal-title":"BMJ"},{"key":"15030095_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000026149","volume":"17","author":"IL Notkola","year":"1998","unstructured":"Notkola IL, et al. (1998). Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer\u2019s disease. Neuroepidemiology 17:14\u201320.","journal-title":"Neuroepidemiology"},{"key":"15030095_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.neurobiolaging.2007.06.005","volume":"30","author":"MT Gentile","year":"2009","unstructured":"Gentile MT, et al. (2009) \u03b2-amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol. Aging 30:222\u20138.","journal-title":"Neurobiol. Aging"},{"issue":"11","key":"15030095_CR21","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1161\/01.STR.0000143452.85382.d1","volume":"35","author":"R Deane","year":"2004","unstructured":"Deane R, Wu Z, Zlokovic BV. (2004) RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid \u03b2-peptide clearance through transport across the blood-brain barrier. Stroke 35(11 Suppl 1):2628\u201331.","journal-title":"Stroke"},{"key":"15030095_CR22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/clinchem\/37.2.241","volume":"37","author":"PR Wenham","year":"1991","unstructured":"Wenham PR, Newton CR, Price WH. (1991) Analysis of apolipoprotein E genotypes by the Amplification Refractory Mutation System. Clin. Chem. 37:241\u20134.","journal-title":"Clin. Chem."},{"key":"15030095_CR23","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1001\/archneur.64.9.1306","volume":"64","author":"RJ Caselli","year":"2007","unstructured":"Caselli RJ, et al. (2007) Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch. Neurol. 64:1306\u201311.","journal-title":"Arch. Neurol."},{"issue":"19","key":"15030095_CR24","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1212\/01.wnl.0000304038.37421.cc","volume":"70","author":"S Cosentino","year":"2008","unstructured":"Cosentino S, et al. (2008) APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology. 70(19 Pt 2):1842\u20139.","journal-title":"Neurology"},{"key":"15030095_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1600-0404.2006.00688.x","volume":"185","author":"K Rockwood","year":"2006","unstructured":"Rockwood K. (2006) Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer\u2019s disease. Acta. Neurol. Scand. Suppl. 185:71\u20137.","journal-title":"Acta. Neurol. Scand. Suppl."},{"key":"15030095_CR26","doi-asserted-by":"crossref","unstructured":"Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. (2008) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry. 2008, Oct 17 [Epub ahead of print].","DOI":"10.1136\/jnnp.2008.150433"},{"key":"15030095_CR27","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2174\/156720508785132316","volume":"5","author":"DL Sparks","year":"2008","unstructured":"Sparks DL, et al. (2008) Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr. Alzheimer Res. 5:416\u201321.","journal-title":"Curr. Alzheimer Res."},{"key":"15030095_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1741-7015-5-20","volume":"5","author":"B Wolozin","year":"2007","unstructured":"Wolozin B, et al. (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson\u2019s disease. BMC Med. 5:20.","journal-title":"BMC Med."},{"key":"15030095_CR29","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2165\/00023210-200721060-00002","volume":"21","author":"K H\u00f6glund","year":"2007","unstructured":"H\u00f6glund K, Blennow K. (2007) Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer\u2019s disease. CNS Drugs 21:449\u201362.","journal-title":"CNS Drugs"},{"key":"15030095_CR30","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jpsychires.2007.10.010","volume":"42","author":"I Blasko","year":"2008","unstructured":"Blasko I, et al. (2008) Effects of medications on plasma amyloid \u03b2 (A\u03b2) 42: longitudinal data from the VITA cohort. J. Psychiatr. Res. 42:946\u201355.","journal-title":"J. Psychiatr. Res."},{"key":"15030095_CR31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0022-2275(20)32074-5","volume":"41","author":"M Sousa","year":"2000","unstructured":"Sousa M, Berglund ML, Saraiva MJ. (2000) Transthyretin in high density lipoproteins: association with apolipoprotein A-I. J. Lipid Res. 41:58\u201365.","journal-title":"J. Lipid Res."},{"key":"15030095_CR32","doi-asserted-by":"publisher","first-page":"7563","DOI":"10.1074\/jbc.270.13.7563","volume":"270","author":"E Matsubara","year":"1995","unstructured":"Matsubara E, Frangione B, Ghiso J. (1995) Characterization of apolipoprotein J-Alzheimer\u2019s A\u03b2 interaction. J. Biol. Chem. 270:7563\u20137.","journal-title":"J. Biol. Chem."},{"key":"15030095_CR33","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1006\/bbrc.1994.2788","volume":"205","author":"A Koudinov","year":"1994","unstructured":"Koudinov A, Matsubara E, Frangione B, and Ghiso J. (1994) The soluble form of Alzheimer\u2019s amyloid \u03b2 protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem. Biophys. Res. Commun. 205:1164\u201371.","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"15030095_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1194\/jlr.C500022-JLR200","volume":"47","author":"LM Wilson","year":"2006","unstructured":"Wilson LM, et al. (2006). High density lipoproteins bind A\u03b2 and apolipoprotein C-II amyloid fibrils. J. Lipid Res. 47:755\u201360.","journal-title":"J. Lipid Res."},{"key":"15030095_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3233\/JAD-2005-8305","volume":"8","author":"K Balakrishnan","year":"2005","unstructured":"Balakrishnan K, et al. (2005). Plasma A\u03b242 correlates positively with increased body fat in healthy individuals. J. Alzheimers Dis. 8:269\u201382.","journal-title":"J. Alzheimers Dis."},{"key":"15030095_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/00002093-200207000-00009","volume":"16","author":"Z Arvanitakis","year":"2002","unstructured":"Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR. (2002) Serum creatinine levels correlate with plasma amyloid \u03b2 protein. Alzheimer Dis. Assoc. Disord. 16:187\u201390.","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"15030095_CR37","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/35102591","volume":"414","author":"S Weggen","year":"2001","unstructured":"Weggen S, et al. (2001). A subset of NSAIDs lower amyloidogenic A\u03b242 independently of cyclooxygenase activity. Nature 414:212\u20136.","journal-title":"Nature"},{"key":"15030095_CR38","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1212\/01.wnl.0000313933.17796.f6","volume":"70","author":"CA Szekely","year":"2008","unstructured":"Szekely CA, et al. (2008) No advantage of A\u03b2 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70:2291\u20138.","journal-title":"Neurology"},{"issue":"4","key":"15030095_CR39","doi-asserted-by":"publisher","first-page":"T165","DOI":"10.1016\/j.jalz.2008.05.432","volume":"4","author":"RC Green","year":"2008","unstructured":"Green RC, Schneider LS, Hendrix SB, Zavitz KH, Swabb E. (2008) Safety and efficacy of tarenflurbil in subjects with mild Alzheimer\u2019s disease: results from an 18-month multi-center phase 3 trial. Alzheimers Dement. 4(4 Suppl):T165.","journal-title":"Alzheimers Dement."},{"issue":"4","key":"15030095_CR40","doi-asserted-by":"publisher","first-page":"T130","DOI":"10.1016\/j.jalz.2008.05.305","volume":"4","author":"JCS Breitner","year":"2008","unstructured":"Breitner JCS (2008). Onset of Alzheimer\u2019s dementia occurs commonly without prior cognitive impairment: results from the Alzheimer\u2019s disease anti-inflammatory prevention trial (ADAPT). Alzheimers Dement. 4(4 Suppl):T130\u20131.","journal-title":"Alzheimers Dement."}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.crossref.org\/molmed.2008.00118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2008.00118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T17:17:23Z","timestamp":1633195043000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.2119\/molmed.2008.00118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":40,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["15030095"],"URL":"https:\/\/doi.org\/10.2119\/molmed.2008.00118","relation":{},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}